Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LGVN Longeveron Inc

Trading 12-11 14:28:36 EST

0.6249

-0.0023

-0.37%

High0.6285	Low0.6005	Vol108.74K
Open0.6285	D1 Closing0.6272	Amplitude4.46%
Mkt Cap13.33M	Tradable Cap10.47M	Total Shares21.33M
T/O66.53K	T/O Rate0.65%	Tradable Shares16.75M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LGVN","market":"US","secType":"STK","nameCN":"Longeveron Inc","latestPrice":0.6249,"timestamp":1765481202112,"preClose":0.6272,"halted":0,"volume":108740,"delay":0,"floatShares":16753800,"shares":21332900,"eps":-2.042737,"marketStatus":"Trading","change":-0.0023,"latestTime":"12-11 14:28:36 EST","open":0.6285,"high":0.6285,"low":0.6005,"amount":66529.067572,"amplitude":0.044643,"askPrice":0.635,"askSize":50,"bidPrice":0.6193,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.042737,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1765486800000},"marketStatusCode":2,"adr":0,"listingDate":1613106000000,"exchange":"NASDAQ","adjPreClose":0.6272,"preHourTrading":{"tag":"盘前","latestPrice":0.646,"preClose":0.6272,"latestTime":"09:15 EST","volume":4386,"amount":2744.1829181999997,"timestamp":1765462505565},"postHourTrading":{"tag":"盘后","latestPrice":0.635,"preClose":0.6272,"latestTime":"19:57 EST","volume":9542,"amount":5969.6159,"timestamp":1765414631651},"volumeRatio":0.417577},"requestUrl":"/m/hq/s/LGVN/wiki","defaultTab":"wiki","newsList":[{"id":"2588402044","title":"Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global Cardiovascular Clinical Trialists (Cvct) Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2588402044","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588402044?lang=en_us&edition=fundamental","pubTime":"2025-12-03 22:15","pubTimestamp":1764771300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUAJTP0C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LGVN"],"gpt_icon":0},{"id":"2588005961","title":"Longeveron Granted Canadian Patent for Stem Cell Therapy Targeting Aging-Related Frailty and Cardiomyopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2588005961","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588005961?lang=en_us&edition=fundamental","pubTime":"2025-12-02 22:15","pubTimestamp":1764684922,"startTime":"0","endTime":"0","summary":"Longeveron Inc. has been granted Canadian Patent No. 3043594, titled \"Method of Using Human Mesenchymal Stem Cells to Effect Cellular and Humoral Immunity.\" The patent covers methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells  for the treatment of aging-related frailty with inflammaging and non-ischemic dilated cardiomyopathy. The patent provides rights in Canada through 2037. Laromestrocel, the company's proprietary MSC therapy, has shown positive initial results in clinical trials for aging-related frailty, a syndrome with no approved treatments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longeveron Inc. published the original content used to generate this news brief via Globe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDLFH2c9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","LU2210149790.SGD","LU2210150020.SGD","IE00B64PRP62.GBP","LU0314104364.USD","NDAQ","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","BK4585","BK4112","BK4139","LU2095319765.USD"],"gpt_icon":0},{"id":"2588059653","title":"Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-Related Frailty in Patients With Inflammaging","url":"https://stock-news.laohu8.com/highlight/detail?id=2588059653","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588059653?lang=en_us&edition=fundamental","pubTime":"2025-12-02 22:15","pubTimestamp":1764684900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA9ZZJPC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGVN","BK4139"],"gpt_icon":0},{"id":"2588477449","title":"Longeveron Stem Cell Therapy Reduces Neuroinflammation in Mild Alzheimer’s Disease, Phase 2 Trial Shows","url":"https://stock-news.laohu8.com/highlight/detail?id=2588477449","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588477449?lang=en_us&edition=fundamental","pubTime":"2025-12-02 01:00","pubTimestamp":1764608425,"startTime":"0","endTime":"0","summary":"Longeveron Inc. announced new data from its Phase 2 placebo-controlled CLEAR-MIND clinical trial evaluating laromestrocel, a stem cell therapy, in patients with mild Alzheimer's disease. The results, presented at the 18th Clinical Trials on Alzheimer's Disease Conference , showed that treatment with laromestrocel was associated with a reduction in MRI-measured neuroinflammation across multiple key brain regions, including the hippocampus. The reduction in hippocampal neuroinflammation correlated with preservation of hippocampal volume and clinical outcomes. The findings support the continued development of laromestrocel for mild Alzheimer's disease.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longeveron Inc. published the original c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL2gZhhX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4139","BK4112","LU2210149790.SGD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LGVN","BK4588","LU0314104364.USD","BK4585","NDAQ","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2588741747","title":"Longeveron New Mri Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients With Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (Ctad 2025)","url":"https://stock-news.laohu8.com/highlight/detail?id=2588741747","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588741747?lang=en_us&edition=fundamental","pubTime":"2025-12-02 01:00","pubTimestamp":1764608400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA1MDRPH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGVN","BK4139"],"gpt_icon":0},{"id":"2584427039","title":"Longeveron Highlights Laromestrocel Data Showing Reduced Brain Neuroinflammation in Mild Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2584427039","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584427039?lang=en_us&edition=fundamental","pubTime":"2025-11-19 22:15","pubTimestamp":1763561710,"startTime":"0","endTime":"0","summary":"Longeveron Inc. announced that data from its clinical study evaluating laromestrocel in mild Alzheimer's disease has been selected for poster presentation at the 18th Clinical Trials on Alzheimer's Disease Conference , scheduled for December 1-4, 2025, in San Diego, California. The presentation, titled \"Reduced brain neuroinflammation after laromestrocel treatment in mild AD: results from the CLEAR MIND study,\" will share findings related to neuroinflammation outcomes following laromestrocel treatment. The results are set to be presented at the conference and have not yet been disclosed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longeveron Inc. published the original content used to generate this news brief via GlobeNewswire  on N","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL3V5QLt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210149790.SGD","LU2210150020.SGD","LGVN","BK4139","NDAQ","IE00BKPKM429.USD","BK4112","BK4588","BK4585","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2095319765.USD"],"gpt_icon":0},{"id":"2584429329","title":"Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (Ctad 2025)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584429329","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584429329?lang=en_us&edition=fundamental","pubTime":"2025-11-19 22:15","pubTimestamp":1763561700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nTUA6ZQLBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LGVN"],"gpt_icon":0},{"id":"2582537734","title":"Longeveron granted U.S. patent for administration of MSCs","url":"https://stock-news.laohu8.com/highlight/detail?id=2582537734","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582537734?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:11","pubTimestamp":1762956690,"startTime":"0","endTime":"0","summary":"Longeveron (LGVN) announced that the United States Patent and Trademark Office, USPTO, has granted a patent covering administration of the Company’...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeveron-granted-u-s-patent-for-administration-of-mscs-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeveron-granted-u-s-patent-for-administration-of-mscs-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LGVN"],"gpt_icon":0},{"id":"2582637215","title":"Longeveron Granted U.S. Patent for Stem Cell Therapy Targeting Aging-Related Frailty","url":"https://stock-news.laohu8.com/highlight/detail?id=2582637215","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582637215?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:05","pubTimestamp":1762956314,"startTime":"0","endTime":"0","summary":"Longeveron Inc. announced that the United States Patent and Trademark Office has granted a patent for methods of treating aging-related frailty in patients with inflammaging using its proprietary mesenchymal stem cell  therapy. The patent, which is valid through 2038, covers the administration of isolated allogeneic MSCs to address symptoms such as weakness, low physical activity, slowed motor performance, exhaustion, and unintentional weight loss in older individuals. The company's lead MSC therapy, laromestrocel, has shown positive initial results in two clinical trials targeting aging-related frailty.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longeveron Inc. published the original content used to generate this news brief via Gl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL702vWZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","LU0314104364.USD","BK4112","BK4139","LU2210149790.SGD","BK4588","IE00BKPKM429.USD","LGVN","BK4585","IE00B64PRP62.GBP","LU2095319765.USD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","NDAQ"],"gpt_icon":0},{"id":"2582965372","title":"Longeveron Granted U.S. Patent for Method of Treating Aging-Related Frailty in Patients With Inflammaging Using Its Proprietary Stem Cell Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2582965372","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582965372?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:05","pubTimestamp":1762956300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA5W8XWB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGVN","BK4139"],"gpt_icon":0},{"id":"2582721013","title":"Longeveron Inc - Patent Rights in U.S. Through 2038","url":"https://stock-news.laohu8.com/highlight/detail?id=2582721013","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582721013?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:05","pubTimestamp":1762956300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA5W8XWB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGVN","BK4139"],"gpt_icon":0},{"id":"2582320291","title":"Longeveron Directors Khoso Baluch and Neha Motwani Resign","url":"https://stock-news.laohu8.com/highlight/detail?id=2582320291","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582320291?lang=en_us&edition=fundamental","pubTime":"2025-11-12 19:21","pubTimestamp":1762946488,"startTime":"0","endTime":"0","summary":"Longeveron Inc. announced that Khoso Baluch and Neha Motwani have resigned from the company's Board of Directors, effective immediately. The company stated that their departures were not due to any disagreement regarding company operations, policies, or management.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longeveron Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 12, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL6XYkcw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN"],"gpt_icon":0},{"id":"2581140440","title":"Longeveron: Promising Outlook with Clinical Progress and Strategic Adjustments","url":"https://stock-news.laohu8.com/highlight/detail?id=2581140440","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581140440?lang=en_us&edition=fundamental","pubTime":"2025-11-07 04:35","pubTimestamp":1762461336,"startTime":"0","endTime":"0","summary":"Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Longeveron. The associated price target remains the same with $4.00. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/longeveron-promising-outlook-with-clinical-progress-and-strategic-adjustments-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/longeveron-promising-outlook-with-clinical-progress-and-strategic-adjustments-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065732104.USD","PRGS","LGVN","BK4139","BK4097"],"gpt_icon":0},{"id":"2581718583","title":"Roth MKM Reaffirms Their Buy Rating on Longeveron (LGVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581718583","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581718583?lang=en_us&edition=fundamental","pubTime":"2025-11-05 10:15","pubTimestamp":1762308933,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Boobalan Pachaiyappan from Roth MKM reiterated a Buy rating on Longeveron, with a price target of $3.00. The compan...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/roth-mkm-reaffirms-their-buy-rating-on-longeveron-lgvn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/roth-mkm-reaffirms-their-buy-rating-on-longeveron-lgvn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LGVN"],"gpt_icon":0},{"id":"2581760039","title":"Longeveron Inc - on Track for Elpis Ii Results in Q3 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2581760039","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581760039?lang=en_us&edition=fundamental","pubTime":"2025-11-05 06:12","pubTimestamp":1762294331,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nFWN3WG20N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LGVN"],"gpt_icon":0},{"id":"2581767215","title":"Cellular therapy developer Longeveron's Q3 net loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2581767215","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581767215?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:53","pubTimestamp":1762293205,"startTime":"0","endTime":"0","summary":"Cellular therapy developer Longeveron's Q3 net loss widensOverviewNet loss for Q3 widened to $7.2 mln, driven by increased R&D expensesCompany anticipates pivotal trial results for laromestrocel in 20","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL1N3WG1FV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","BK4139"],"gpt_icon":0},{"id":"2581647777","title":"Longeveron Q3 EPS USD -0.39","url":"https://stock-news.laohu8.com/highlight/detail?id=2581647777","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581647777?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:23","pubTimestamp":1762291384,"startTime":"0","endTime":"0","summary":"Nov 04 (Reuters) - Longeveron Q3 revenue USD 94 thousand.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 04-NOV-202521:05:50.167 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nRSD9JDmKz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN"],"gpt_icon":0},{"id":"2581769120","title":"Longeveron Q3 Operating Expenses USD 7.435 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581769120","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581769120?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:05","pubTimestamp":1762290307,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nPLX4A7FF1:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGVN","BK4139"],"gpt_icon":0},{"id":"2581769306","title":"Longeveron Q3 EPS $(0.39) Misses $(0.26) Estimate, Sales $137.000K Miss $284.667K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581769306","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581769306?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:03","pubTimestamp":1762290236,"startTime":"0","endTime":"0","summary":"Longeveron Q3 EPS $(0.39) Misses $(0.26) Estimate, Sales $137.000K Miss $284.667K Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48636799/longeveron-q3-eps-0-39-misses-0-26-estimate-sales-137-000k-miss-284-667k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Longeveron Q3 EPS $(0.39) Misses $(0.26) Estimate, Sales $137.000K Miss $284.667K Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN"],"gpt_icon":0},{"id":"2578950563","title":"Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2578950563","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578950563?lang=en_us&edition=fundamental","pubTime":"2025-10-28 21:15","pubTimestamp":1761657300,"startTime":"0","endTime":"0","summary":"MIAMI, Oct.  28, 2025  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-r","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/28/3175547/0/en/Longeveron-to-Report-Third-Quarter-2025-Financial-Results-and-Host-Conference-Call-on-November-4-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","BK4218","BK4575","MSC","BK4585","BK4181","BK4139","BK4588","BK4150","HST"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.longeveron.com","stockEarnings":[{"period":"1week","weight":-0.0146},{"period":"1month","weight":-0.1543},{"period":"3month","weight":-0.2111},{"period":"6month","weight":-0.5175},{"period":"1year","weight":-0.68},{"period":"ytd","weight":-0.6375}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.209988},{"month":2,"riseRate":0,"avgChangeRate":-0.057793},{"month":3,"riseRate":0.4,"avgChangeRate":0.047866},{"month":4,"riseRate":0.4,"avgChangeRate":-0.129651},{"month":5,"riseRate":0.4,"avgChangeRate":-0.141174},{"month":6,"riseRate":0.8,"avgChangeRate":0.122312},{"month":7,"riseRate":0.6,"avgChangeRate":0.185232},{"month":8,"riseRate":0,"avgChangeRate":-0.329414},{"month":9,"riseRate":0.2,"avgChangeRate":-0.104571},{"month":10,"riseRate":0.4,"avgChangeRate":-0.0027},{"month":11,"riseRate":0.4,"avgChangeRate":1.29104},{"month":12,"riseRate":0,"avgChangeRate":-0.245537}],"exchange":"NASDAQ","name":"Longeveron Inc","nameEN":"Longeveron Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Longeveron Inc(LGVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Longeveron Inc,LGVN,Longeveron Inc股票,Longeveron Inc股票老虎,Longeveron Inc股票老虎国际,Longeveron Inc行情,Longeveron Inc股票行情,Longeveron Inc股价,Longeveron Inc股市,Longeveron Inc股票价格,Longeveron Inc股票交易,Longeveron Inc股票购买,Longeveron Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Longeveron Inc(LGVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}